NBP — NovaBridge Biosciences Share News
0.000.00%
Last trade - 00:00- $158.92m
- -$31.93m
AbbVie terminates deal with I-Mab to develop cancer drug (updated)
AbbVie terminates deal with I-Mab to develop cancer drug
I-Mab expected to post a loss of 28 cents a share - Earnings Preview
I-Mab appoints new CEO, shares fall
Brief: I-Mab Announces The Appointment Of Raj Kannan As CEO
Brief: I-Mab Announces Phase 1B/2 Study Results Of Patients With Advanced Nsclc Receiving Uliledlimab And Toripalimab Combination Therapy
Tracon Pharma Down After Unfavorable Ruling In Dispute With I: MAB
Brief: I-Mab Announces Positive Outcome In Arbitration Relating To Agreements With Tracon
Brief: I-Mab Provides Business And Corporate Updates And Reports Financial Results For The Year Ended December 31, 2022
Refile: BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Starbucks, ASLAN Pharma
U.S. STOCKS ON THE MOVE-Jasper Therapeutics, Blackstone, Mondelez
U.S. STOCKS ON THE MOVE-Horizon Global, Apple, PayPal Holdings
Jefferies sees opportunity in biotech stocks trading below cash level
Brief: I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study
Brief: I-Mab Announces Positive Phase 2 Data Of Lemzoparlimab In Combination With Azacitidine In Patients With Higher Risk Myelodysplastic Syndrome
Brief: I-Mab announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at Esmo Congress 2022
Brief: I-Mab Reports Financial Results For Six Months Ended June 30, 2022
Brief: I-Mab Announces Share Purchase Plans By The Company And Senior Management
U.S. RESEARCH ROUNDUP- Analog Devices, Bath & Body Works, Synopsys